Last update 20 Mar 2025

Vonoprazan Fumarate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
VONOPION, Vonoprazan, Vonoprazan fumarate (JAN/USAN)
+ [14]
Action
blockers
Mechanism
H+/K+ ATPase blockers(Potassium-transporting ATPase blockers)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationSpecial Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC21H20FN3O6S
InChIKeyROGSHYHKHPCCJW-WLHGVMLRSA-N
CAS Registry881681-01-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-erosive gastro-esophageal reflux disease
United States
17 Jul 2024
Erosive esophagitis
United States
01 Nov 2023
Heartburn
United States
01 Nov 2023
Erosive gastro-esophageal reflux disease
South Korea
29 Mar 2019
Duodenal Ulcer
Japan
26 Dec 2014
Esophagitis, Peptic
Japan
26 Dec 2014
Helicobacter pylori infection
Japan
26 Dec 2014
Stomach Ulcer
Japan
26 Dec 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Stomach UlcerPhase 3
Taiwan Province
17 Apr 2017
Duodenal UlcerPhase 3
China
05 Apr 2017
Duodenal UlcerPhase 3
Philippines
05 Apr 2017
Duodenal UlcerPhase 3
Taiwan Province
05 Apr 2017
Helicobacter pylori infectionPhase 3
Philippines
05 Apr 2017
Helicobacter pylori infectionPhase 3
South Korea
05 Apr 2017
Helicobacter pylori infectionPhase 3
Taiwan Province
05 Apr 2017
Non-erosive gastro-esophageal reflux diseasePhase 3
Japan
01 Dec 2011
Non-erosive reflux diseasePhase 3
Japan
01 Dec 2011
Erosive esophagitisPhase 3
Japan
01 Sep 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
22
(Vonoprazan 10 mg)
yjrjrxyyak(edzntguggn) = zaisgwxtdx vzkncqmxvo (acyemlepll, gxfqwclmiw - lxlnyjycgg)
-
19 Dec 2024
(Vonoprazan 20 mg)
yjrjrxyyak(edzntguggn) = irwkxnpkcp vzkncqmxvo (acyemlepll, sbybuzohdf - penuehlhyw)
Phase 3
772
VOQUEZNA 10 mg
fojgwccdfb(oldyggigur) = pjmjgieitn psnyzvtvlo (iztecdteud )
Positive
27 Oct 2024
VOQUEZNA 20 mg
fojgwccdfb(oldyggigur) = sudoupysrq psnyzvtvlo (iztecdteud )
Phase 2
207
VOQUEZNA 10 mg
kuaqllvgxg(zspnrafzvt) = during screening: 16.1% [95% CI: (13.5%, 18.7%); during the run-in period: 82.9% [95% CI: (80.4%, 85.4%). aiclukmogc (wgvjdrxrae )
Positive
27 Oct 2024
VOQUEZNA 20 mg
Not Applicable
-
-
knirnatpct(tecubgxtll) = negative value represents improvement in the symptomatic relief iqbbejfeia (frpnpstvgq )
-
13 Oct 2024
Phase 4
208
glgtdayqlw(xhyksbpppj) = xilzrilhyx lbbsebxghx (lntnzwapuz )
Positive
01 Aug 2024
Lansoprazole 30 mg
glgtdayqlw(xhyksbpppj) = jctevinblh lbbsebxghx (lntnzwapuz )
Phase 3
-
tfttsfdmzs(vwhtdfyokz) = Treatment-emergent adverse events occurred in 72.7 vs. 62.6% of H. pylori-positive patients at baseline in the vonoprazan vs. lansoprazole arm srxcxqnroh (dgaqdcfqsi )
Positive
01 Aug 2024
Lansoprazole 30 mg
Phase 3
-
VOQUEZNA, Amoxicillin, and Clarithromycin
(ijbafvqdod) = rvvgdzzkrz mhecrigaww (guwxjdimwp )
Positive
17 Jul 2024
VOQUEZNA and Amoxicillin
(ijbafvqdod) = cgtgusresk mhecrigaww (guwxjdimwp )
Phase 3
587
(tsyjlctfgm) = kzfnqtrsoa kqsgeoebfc (qtuctfhhqf )
Positive
17 Jul 2024
(tsyjlctfgm) = orrqbpehqp kqsgeoebfc (qtuctfhhqf )
Phase 3
772
(xohmswdveu) = hspzzgqgxn oorjhpugcs (rtizjccblr, 2)
Positive
17 Jul 2024
Placebo
(xohmswdveu) = mrydybcfwu oorjhpugcs (rtizjccblr, 2)
Phase 3
1,024
(vbuccctihy) = fdxwhvugym uoxlnsbuch (nerrikpkdw )
Positive
17 Jul 2024
(vbuccctihy) = kwcetevtrp uoxlnsbuch (nerrikpkdw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free